NASDAQ · DYAI
Healthcare · Biotechnology
$0.48
Down-$0.01 (-1.18%)
Updated Sep 14, 2026, 2:00 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
DYAI closed at $0.48 after 19 trading sessions, down 37.97% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $0.501 | $0.5189 | $0.46 | $0.484 | 148.46K |
| Sep 10, 2026 | $0.51 | $0.51 | $0.4821 | $0.4898 | 89.9K |
| Sep 9, 2026 | $0.53 | $0.53 | $0.5012 | $0.5139 | 57.69K |
| Sep 8, 2026 | $0.536 | $0.5796 | $0.51 | $0.5201 | 155.65K |
| Sep 4, 2026 | $0.50 | $0.533 | $0.4821 | $0.5202 | 126.94K |
| Sep 3, 2026 | $0.521 | $0.5551 | $0.4821 | $0.5007 | 309.22K |
| Sep 2, 2026 | $0.5275 | $0.5562 | $0.5001 | $0.5242 | 124.86K |
| Sep 1, 2026 | $0.551 | $0.58 | $0.508 | $0.5321 | 398.49K |
| Aug 31, 2026 | $0.6196 | $0.637 | $0.5127 | $0.5551 | 261.91K |
| Aug 28, 2026 | $0.65 | $0.6616 | $0.60 | $0.6141 | 276.7K |
| Aug 27, 2026 | $0.689 | $0.6905 | $0.6197 | $0.6391 | 179.9K |
| Aug 26, 2026 | $0.6989 | $0.7193 | $0.651 | $0.6601 | 80.79K |
| Aug 25, 2026 | $0.70 | $0.7198 | $0.681 | $0.691 | 57.83K |
| Aug 24, 2026 | $0.71 | $0.7339 | $0.6701 | $0.6793 | 67.46K |
| Aug 21, 2026 | $0.708 | $0.735 | $0.68 | $0.69 | 116.18K |
| Aug 20, 2026 | $0.7364 | $0.7549 | $0.70 | $0.70 | 57.17K |
| Aug 19, 2026 | $0.7572 | $0.7606 | $0.731 | $0.7389 | 75.84K |
| Aug 18, 2026 | $0.7801 | $0.7909 | $0.7502 | $0.7641 | 164.72K |
| Aug 17, 2026 | $0.746 | $0.8104 | $0.746 | $0.7803 | 345.79K |
The latest Smart Investors Daily articles mentioning DYAI.
DYAI research
Company profile and research snapshot.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | Buy | — |
| Jul 8, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 13, 2023 | HC Wainwright & Co. | Buy | — |
| May 24, 2023 | HC Wainwright & Co. | Buy | — |
| Feb 3, 2023 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 4, 2026
Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food
Benzinga · Jul 24, 2026
Dyadic International, Inc. (NASDAQ:DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food
Benzinga · Mar 2, 2026
Completion of these development activities represents a contractual milestone under the parties' 2023 development and commercialization agreement focused on non-animal dairy enzymes produced using Dyadic's proprietary
Benzinga · Feb 17, 2026
Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DYAI.
